We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Individual Patient Compassionate Use of Nirogacestat

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT05041036
Expanded Access Status : Available
First Posted : September 10, 2021
Last Update Posted : September 10, 2021
Information provided by (Responsible Party):
SpringWorks Therapeutics, Inc.

Brief Summary:
This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee and Single Patient IND approval.

Condition or disease Intervention/treatment
Desmoid Tumor NOTCH Gene Mutation Positive Tumors Drug: Nirogacestat (Gamma Secretase Inhibitor)

Layout table for study information
Study Type : Expanded Access
Expanded Access Type : Individual Patients
  See clinical trials of the intervention/treatment in this expanded access record.
Official Title: Individual Patient Compassionate Use of Nirogacestat

Intervention Details:
  • Drug: Nirogacestat (Gamma Secretase Inhibitor)
    Patients will receive nirogacestat tablets to be taken orally.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Patient has a serious, debilitating or life-threatening medical condition with no suitable treatment available, has exhausted current standard of care or declined medically-appropriate treatment for ethical or medical reasons.
  • Patient does not qualify to participate in any ongoing clinical trial sponsored by SpringWorks in an accessible geographical location.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05041036

Layout table for location contacts
Contact: Sue Scott 203-883-9490 medinfo@springworkstx.com
Contact: Pamela Papino-Wood 203-883-9490 medinfo@springworkstx.com

Sponsors and Collaborators
SpringWorks Therapeutics, Inc.
Layout table for additonal information
Responsible Party: SpringWorks Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT05041036    
Other Study ID Numbers: NIR-DT-701
First Posted: September 10, 2021    Key Record Dates
Last Update Posted: September 10, 2021
Last Verified: July 2021
Keywords provided by SpringWorks Therapeutics, Inc.:
desmoid tumor
aggressive fibromatosis
desmoid fibromatosis
Notch-positive tumors
Additional relevant MeSH terms:
Layout table for MeSH terms
Fibromatosis, Aggressive
Neoplasms, Fibrous Tissue
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type